Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

2.33
-0.1200-4.90%
Post-market: 2.440.1126+4.83%19:59 EDT
Volume:1.70M
Turnover:4.07M
Market Cap:279.60M
PE:-2.21
High:2.51
Open:2.46
Low:2.32
Close:2.45
52wk High:3.23
52wk Low:0.9335
Shares:120.00M
Float Shares:104.94M
Volume Ratio:0.95
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0528
EPS(LYR):-1.1500
ROE:-60.75%
ROA:-26.22%
PB:1.82
PE(LYR):-2.03

Loading ...

Fate Therapeutics intiates first patient in RECLAIM-LN trial

TIPRANKS
·
Aug 16

Fate Therapeutics Price Target Maintained with a $7.00/Share by Wedbush

Dow Jones
·
Aug 14

Fate Therapeutics - Patients to Receive Single 900 Mln-Cell Dose of Ft819; Primary Endpoint at Week 26

THOMSON REUTERS
·
Aug 14

Fate Therapeutics Initiates Potentially Registrational Reclaim-Ln Clinical Trial of FT819 for the Treatment of Lupus Nephritis

THOMSON REUTERS
·
Aug 14

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

GlobeNewswire
·
Aug 14

Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives

Reuters
·
Aug 14

Analysts Conflicted on These Healthcare Names: Fate Therapeutics (FATE) and Mediwound (MDWD)

TIPRANKS
·
Aug 14

Fate Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate

Benzinga Earnings
·
Aug 13

Fate Therapeutics - Expects Operating Runway into 2028

THOMSON REUTERS
·
Aug 13

Fate Therapeutics Q2 Operating Expenses USD 33.216 Million

THOMSON REUTERS
·
Aug 13

Fate Therapeutics Inc Expected to Post a Loss of 27 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Don't Ignore The Insider Selling In Fate Therapeutics

Simply Wall St.
·
Aug 07

Fate Therapeutics Inc Expected to Post a Loss of 27 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Fate Therapeutics Grants New-Hire Inducement Equity Awards, Including 37,300 Options at $2.45

Reuters
·
Aug 04

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 04

Sector Update: Healthcare

MT Newswires Live
·
Jul 10

Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839

MT Newswires Live
·
Jul 10

Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed

TIPRANKS
·
Jul 09

Fate Therapeutics Wins FDA IND Clearance for Dual-target CAR-T Candidate FT839

Reuters
·
Jul 09